Article

Generic versions of oxybutynin gain approval for OAB

The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder.

The FDA has granted approval to two generic versions of extended-release oxybutynin chloride for the treatment of overactive bladder. Mylan Laboratories received final approval for 5- and 10-mg extended-release tablets, and IMPAX Laboratories received approval for 15-mg extended-release tablets. Both companies said the products would be launched immediately.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman talking with doctor | Image Credit: © LuneVA/peopleimages.com - stock.adobe.com
Timothy D. Lyon, MD, answers a question during a video interview
Amy E. Krambeck, MD, answers a question during a Zoom video interview
Related Content
US FDA logo in white over a blue background. | Credit: US Food and Drug Administration
February 4th 2025

FDA Updates in Urology: January 2025

Patrick Campbell
A recap of the FDA submissions and regulatory decisions in urology from January 2025.
Site Logo
January 29th 2025

Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD
Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.
Urologist speaking with a male patient following a diagnosis of cancer. | Credit: Adobe Stock
February 4th 2025

Urologic Cancer Facts and Updates for World Cancer Day 2025

Patrick Campbell
A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.
Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges
January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD
Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.
Female medical professional with tablet computer talking to older man about his health | Image Credit: © rocketclips - stock.adobe.com
February 3rd 2025

AI and wearables: The new age of smart sex

Dayna R. Smerina Amy M. Pearlman, MD
"Wearable devices are increasingly being used to understand and improve male sexual dysfunctions," write the authors.
Hundreds of future urologists celebrate Urology Match Day 2025
February 3rd 2025

Hundreds of future urologists celebrate Urology Match Day 2025

Hannah Clarke
Overall, 403 medical students and other applicants were matched across 148 urology residency programs nationwide.
© 2025 MJH Life Sciences

All rights reserved.